Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jeffrey Ubben Has a Surprise Entry Among His Top Stock Picks

Page 1 of 2

It is not every quarter that you get to spot drastic changes in the equity portfolio of Jeffrey Ubben‘s ValueAct Capital. The fund invests with a long term perspective and the average holding period of its stock picks is in the vicinity of three years. However, there was a surprise packed in for investors tracking ValueAct Capital, according to the firm’s latest 13F filing with the SEC for the reporting period of March 31.


Prior to establishing ValueAct in 2000, Ubben served for five years in Richard Blum‘s Blum Capital Partners as a Managing Partner. ValueAct is a relatively large fund with $19.4 billion in assets under management. The market value of its equity portfolio increased to $18.09 billion from $15.96 billion at the end of the fourth quarter. The technology and healthcare sectors contributed the most to this value, with the top holdings being Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Microsoft Corporation (NASDAQ:MSFT), and Halliburton Company (NYSE:HAL). As is expected of long-term investing, the turnover ratio of 20% for the first quarter was towards the lower end. ValueAct also has a concentrated portfolio with a total of 15 holdings, with its top three picks constituting nearly 47% of the fund’s portfolio value.

As far as the importance of tracking hedge funds like ValueAct Capital is concerned, we discovered through our research that a portfolio of the 15 most popular small-cap picks of hedge funds beat the S&P 500 Total Return Index by nearly a percentage point per month between 1999 and 2012. On the other hand the most popular large-cap picks of hedge funds underperformed the same index by seven basis points per month during the same period. In forward tests since August 2012 through April 2015 our strategy beat the market by more than 80 percentage points (read the details here), returning 139%. Hence a retail investor needs to isolate himself from the herd of investors chasing large-cap stocks and take advantage of the prevalent arbitrage opportunities in the market by concentrating on these money-making small-cap stocks.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was ValueAct’s largest holding and remained unchanged at 19.39 million shares, valued at $3.85 billion. It represented about 21.28% of the fund’s portfolio value. The stock has appreciated by a staggering 57% so far this year. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reported impressive first quarter financial results, posting a 108% increase in net income from the same quarter last year with an EPS of $0.21, while revenues of $2.19 billion also marked a 15.9% increase on a year-over-year basis. During the company’s earnings call, Mike Pearson, CEO of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced that the the latest acquisitions of Dandreon and Salix have almost been integrated and that the company expects that synergies from Salix will exceed $530 million, most of it being realized by the end of the second quarter. Meanwhile, Dandreon’s $130 million in synergies will most likely be realized by the end of this year. After ValueAct, Andreas Halvorsen‘s Viking Global and Stephen Mandel’s Lone Pine Capital are the second and third-largest stockholders of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) respectively, among the funds we track.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!